Persistence of interleukin (IL)-17A+ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy.
Division of Dermatology, McGill University, Montréal, QC, Canada.
C
C
Jack
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.
S
S
Mashiko
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.|Department of Neurosciences, Université de Montréal, Montréal, QC, Canada.
N
N
Arbour
Innovaderm Research, Montréal, QC, Canada.
R
R
Bissonnette
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.
M
M
Sarfati
D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D020381:Interleukin-17 / Q000378:metabolism*; D007378:Interleukins / Q000378:metabolism; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D012333:RNA, Messenger / Q000378:metabolism; D018123:Receptors, Interleukin / Q000378:metabolism; D012867:Skin / Q000276:immunology; D058504:Th17 Cells / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D000069549:Ustekinumab / Q000627:therapeutic use*; D000097043:Interleukin-22
D003879:Dermatologic Agents; D007371:Interferon-gamma; D020381:Interleukin-17; D007378:Interleukins; D012333:RNA, Messenger; D018123:Receptors, Interleukin; D014409:Tumor Necrosis Factor-alpha; D000069549:Ustekinumab; D000097043:Interleukin-22; C508717:IL17A protein, human; C415369:interleukin-22 receptor